Ngā kupu hautoa kōpae
Tohutoro APA (7th ed.)
Ravi Ramessur, M., Zelma C. Chiesa Fuxench, M., Daniel Shin, P., Jennifer B. Mason, M., Anabel C. Mason, B., Maryte Papadopoulos, M., . . . Joel M. Gelfand, M. (2026). Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial. Elsevier.
I tāruatia paitia ki te papatopenga
Kua rahua te tārua ki te papatopenga
Tohutoru Kātū Chicago (17th ed.)
Ravi Ramessur, MD, MD Zelma C. Chiesa Fuxench, PhD Daniel Shin, MPH Jennifer B. Mason, BS Anabel C. Mason, MBE Maryte Papadopoulos, MD Bruna Galvao de Oliveira Wafae, MD Megan H. Noe, me MD Joel M. Gelfand. Deucravacitinib for the Treatment of Moderate-to-severe Palmoplantar Pustulosis: Results from an Early-terminated Open-label Trial. Elsevier, 2026.
I tāruatia paitia ki te papatopenga
Kua rahua te tārua ki te papatopenga
Tohutoro MLA (9th ed.)
Ravi Ramessur, MD, et al. Deucravacitinib for the Treatment of Moderate-to-severe Palmoplantar Pustulosis: Results from an Early-terminated Open-label Trial. Elsevier, 2026.
I tāruatia paitia ki te papatopenga
Kua rahua te tārua ki te papatopenga
Kia tūpato: Kāore pea ēnei kupu hautoa i te ōrite pū 100%.